Heron Therapeutics объявляет об успешном исходе встречи FDA Type A для обсуждения HTX-011 для лечения послеоперационной боли

Heron Therapeutics announces successful outcome of FDA Type A meeting Heron Therapeutics announced a successful Type A meeting with the U.S. FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application for HTX-011 for the management of postoperative pain in the fourth quarter of this year.